IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial

Courtney Crim, Sally Stone, Valerie Millar, Sally Lettis, Elisabeth H. Bel, Andrew Menzies-Gow, Pascal Chanez, Sally Wenzel, Njira Lugogo, Eugene R. Bleecker

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Most biologics for severe asthma target only type 2 immunity. Inhibition of IL-33 signaling has the potential to target type 2 and non–type 2 pathways. Objective: This multicenter phase IIA study evaluated the safety and efficacy of GSK3772847, a human mAb directed against the IL-33 receptor (IL-33R) in subjects with moderate-to-severe uncontrolled asthma. Methods: Adults with uncontrolled asthma despite inhaled corticosteroid/long-acting β2-agonist therapy received equivalent replacement medication (open-label fluticasone propionate/salmeterol [500/50 μg, twice daily]) for 2 weeks before randomization at week 0. At weeks 0, 4, 8, and 12, participants were administered blinded placebo or 10 mg/kg of intravenous GSK3772847. At week 2, salmeterol was discontinued; thereafter, fluticasone propionate was titrated by approximately 50% on weeks 4, 6, 8, and 10. Asthma control was assessed until week 16. Participants with loss of asthma control discontinued treatment. The primary end point was loss of asthma control; secondary end points were the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of GSK3772847. Results: At week 16, 56 participants (81%) and 45 (66%) receiving placebo and GSK3772847, respectively, had loss of asthma control (an 18% reduction [95% credible interval = 2%-35%]). Early loss of asthma control prevented full analysis of the secondary efficacy end points after week 4. The most frequent classes of treatment-related adverse events were cardiac disorders (n = 3 [4%] in both groups) and musculoskeletal/connective tissue disorders (with GSK3772847, n = 3 [4%]; with placebo n = 0). Target engagement of IL-33R by GSK3772847 was demonstrated. Conclusion: Treatment with GSK3772847 may be beneficial for patients with uncontrolled asthma. Further studies are warranted.

Original languageEnglish (US)
Pages (from-to)198-208
Number of pages11
JournalJournal of Allergy and Clinical Immunology: Global
Issue number4
StatePublished - Nov 2022
Externally publishedYes


  • Asthma
  • GSK37772847
  • IL-1 receptor-like 1 protein
  • IL-33
  • mAb
  • placebo-controlled trial
  • randomized trial

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this